Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -81% Improvement Relative Risk Mohandas et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 3,345 patients in India Higher mortality with HCQ (p=0.0067) Mohandas et al., Favors HCQ Favors control
Clinical review of COVID-19 patients presenting to a quaternary care private hospital in South India: A retrospective study
Mohandas et al.,
Mohandas et al., Clinical review of COVID-19 patients presenting to a quaternary care private hospital in South India: A..,
Apr 2021   Source   PDF  
  All Studies   Meta
Retrospective 3,345 hospitalized patients in India, 11.5% treated with HCQ, showing unadjusted higher mortality with treatment. Confounding by indication and time based confounding (due to declining use over the period when overall treatment protocols improved dramatically) are likely. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; unadjusted results with no group details; substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
risk of death, 81.0% higher, RR 1.81, p = 0.007, treatment 27 of 384 (7.0%), control 115 of 2,961 (3.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mohandas et al., 26 Apr 2021, retrospective, India, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Epidemiology and Global Health 11 (2021) 100751 Contents lists available at ScienceDirect Clinical Epidemiology and Global Health journal homepage: Original article Clinical review of COVID-19 patients presenting to a quaternary care private hospital in South India: A retrospective study Prithvi Mohandas *, Sathya Periasamy, Manimaran Marappan, Arun Sampath, Vanaja Kate Garfin Sundaram, Vijit Koshy Cherian MIOT International Hospital, Chennai, Tamil Nadu, 600089, India A R T I C L E I N F O A B S T R A C T Keywords: COVID-19 Epidemiology Risk factors SARS-CoV-2 South India Background: Coronavirus disease 2019 (COVID-19) has been declared a global public-health crisis due to its impact on health, economy, and mental well-being. Here, we evaluated the clinical and epidemiological pa­ rameters associated with COVID-19 in South India. Methods: A retrospective, quaternary care hospital-based study that included COVID-19 positive patients admitted to MIOT International Hospital, Chennai between 8 April–7 August 2020. Cases were identified by reverse transcriptase-polymerase chain reaction. Epidemiological, demographic, clinical, and radiological find­ ings were recorded and analyzed. The primary endpoint was stable discharge from hospital/patient recovery or death. Associations between risk factors and comorbidities were analyzed using Chi-Square/Fisher’s exact test. Results: Of the 5264 cases reviewed, 3345 cases were included. The mean (standard deviation, SD) age of the patients was 47.58 (16.69) years with a median and range hospital stay of 5 (2–41) days. 69.20% of patients were male. The most frequent comorbidities were diabetes (37.10%) and hypertension (29.10%). Contact history was available for 58% of patients. The most common symptoms were cough (36.60%), fever (28.30%), and myalgia (15.40%). Abnormal chest radiography was reported in 16.9% of patients. Phase of admission, age ≥50 years, hypertension, diabetes, coronary artery disease, chronic kidney disease was significantly associated with mor­ tality (p < 0.05). There were 142 (4.2%) deaths in this study. Conclusion: In this single centre hospital-based study, late presentation and more severe form of COVID pneu­ monia lead to higher mortality although it had lower mortality rate for COVID-19 in comparison. Late phase of the pandemic showed better outcomes vs. the early group.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop